Vivos, Inc. Completes Common Stock Equity Financing to Fund Roll Out of IsoPet™ and Eliminate Toxic Debt
October 10, 2018 07:00 ET
|
Vivos Inc.
Richland WA, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL) Vivos, Inc. a pharmaceutical company researching and developing minimally invasive treatments to combat cancer in humans...
Vivos Inc Signs Memorandum of Understanding with Private Veterinary Hospital as Pilot Clinic for Commercial IsoPet® Therapy
October 02, 2018 07:00 ET
|
Vivos Inc.
Richland, WA, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) selected its first clinic for commercial sales of IsoPet Vivos Inc., a pharmaceutical company in the process of researching and...
Vivos Inc Successfully Treats Canine Sarcoma with IsoPet™ (RadioGel™)
May 31, 2018 06:00 ET
|
Vivos Inc.
Richland, WA, May 31, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) successfully treated canine soft tissue sarcoma with its proprietary IsoPet™ (RadioGel™), a hydrogel liquid containing tiny...
Vivos Demonstrates that IsoPet™ (RadioGel™) is effective in killing cancer in cats
May 01, 2018 09:00 ET
|
Vivos Inc.
Richland, WA, May 01, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today the results from the therapy for feline sarcoma. Five cats were treated at Washington...
Vivos Adds Commercial Expertise to its Veterinary Medicine Advisory Board
March 20, 2018 09:30 ET
|
Vivos Inc.
Richland, WA, March 20, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today that it added a new member on the Veterinary Medicine Advisory Board. Tariq Shah BSc. DipMS is the...
Vivos Receives FDA Confirmation of RadioGel Device Classification for Animal Skin Cancer Therapy
January 30, 2018 09:00 ET
|
Vivos Inc.
Richland, WA, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today that it has been notified by the FDA that RadioGel™ is classified as a device for animal therapy. ...
Vivos Completes Planned Dosing Schedule for Feline Sarcoma Program
January 12, 2018 11:54 ET
|
Vivos Inc.
Richland, WA, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today that it has completed its planned dosing schedule to determine the effectiveness of using the Company’s...